Asia Pacific Spinal Cord Stimulation Devices Market: By Product Type (Rechargeable Devices and Non-Rechargeable Devices), By Application (Failed Back Surgery Syndrome (FBSS), Complex Regional Pain Syndrome (CRPS), Ischemic Pain, and Others), By End-User (Hospitals, Ambulatory Surgical Centers, and Neuro Clinics), and Country (Japan, China, India, Australia & New Zealand, ASEAN, South Korea, and Rest of Asia-Pacific)  

Asia Pacific Spinal Cord Stimulation Devices Market size was valued at US$ 271.3 billion in 2023 and is poised to grow at a CAGR of 11.2% from 2024-2030.  The patients' preferred method of internal neurostimulation is spinal cord stimulation. The spinal cord stimulation device employs a device to provide electrical impulses to the vagus nerve. The FDA has currently approved the use of an implanted spinal cord stimulator to treat depression and epilepsy. Each side of the body has one vagus nerve, which travels from the brainstem via the neck to the chest and abdomen. Software developments like closed-loop stimulation and remote programming will make internal neurostimulation devices a more individualized and approachable technology in the future. It is anticipated that internal neurostimulation technology will continue to enhance quality of life. The market is expected to expand as a result of factors including the increased frequency of spinal illnesses and chronic lower back pain in combination with the availability of medical reimbursements. A spinal cord injury is thought to affect roughly 296,000 persons in the United States, according to a report from the National Spinal Cord Injury Statistical Centre from June 2021. Approximately 78% of spinal cord injury cases in this demographic are male, whereas 22% are female.